Literature DB >> 33260809

Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.

Bertram Flehmig1,2, Michael Schindler3, Natalia Ruetalo3, Ramona Businger3, Manfred Bayer4, Angelika Haage2, Thomas Kirchner5, Karin Klingel6, Andrea Normann2, Lutz Pridzun2, Despina Tougianidou4, Michael B Ranke1.   

Abstract

The relationship between the nasopharyngeal virus load, IgA and IgG antibodies to both the S1-RBD-protein and the N-protein, as well as the neutralizing activity (NAbs) against SARS-CoV-2 in the blood of moderately afflicted COVID-19 patients, needs further longitudinal investigation. Several new serological methods to examine these parameters were developed, validated and applied in three patients of a family which underwent an ambulatory course of COVID-19 for six months. The virus load had almost completely disappeared after about four weeks. Serum IgA levels to the S1-RBD-protein and, to a lesser extent, to the N-protein, peaked about three weeks after clinical disease onset but declined soon thereafter. IgG levels rose continuously, reaching a plateau at approximately six weeks, and stayed elevated over the observation period. Virus-neutralizing activity reached a peak about 4 weeks after disease onset but dropped slowly. The longitudinal associations of virus neutralization and the serological immune response suggest immunity in patients even after a mild clinical course of COVID-19.

Entities:  

Keywords:  COVID-19; SARS-CoV-2 N-protein; SARS-CoV-2 RT-qPCR; SARS-CoV-2 S1-RDB protein; SARS-CoV-2 neutralizing activity; anti-SARS-CoV-2 antibodies

Year:  2020        PMID: 33260809     DOI: 10.3390/v12121357

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  8 in total

1.  A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus.

Authors:  Md Omar Faruque; Md Shaid Bin Islam; Hedayet Ullah; K M Kaderi Kibria; Shafi Mahmud; Mojnu Miah; Amani Ali Saleh
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-25       Impact factor: 5.560

2.  Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody.

Authors:  Giovanna Moscato; Paola Mazzetti; Ersilia Lucenteforte; Alfredo Rosellini; Alice Cara; Paola Quaranta; Valerio Mainardi; Pietro Villa; Daniele Focosi; Maria Lanza; Irene Bianco; Alessandro Mazzoni; Marco Falcone; Francesco Menichetti; Fabrizio Maggi; Michele Lai; Giulia Freer; Mauro Pistello
Journal:  J Clin Virol Plus       Date:  2021-05-04

3.  SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.

Authors:  Tatsuya Yoshihara; Kazuya Ito; Masayoshi Zaitsu; Eunhee Chung; Izumi Aoyagi; Yoshikazu Kaji; Tomomi Tsuru; Takuma Yonemura; Koji Yamaguchi; Shinichi Nakayama; Yosuke Tanaka; Nobuo Yurino; Hideki Koyanagi; Shunji Matsuki; Ryuji Urae; Shin Irie
Journal:  Int J Environ Res Public Health       Date:  2021-04-05       Impact factor: 3.390

Review 4.  [Biology and pathology of coronaviruses].

Authors:  Selina Traxler; Michael Schindler; Hans Bösmüller; Karin Klingel
Journal:  Pathologe       Date:  2021-03-01       Impact factor: 0.973

5.  Anti-spike S1 receptor-binding domain antibodies against SARS-CoV-2 persist several months after infection regardless of disease severity.

Authors:  Davide F Bavaro; Paola Laghetti; Eugenio Milano; Gaetano Brindicci; Anna Volpe; Antonella Lagioia; Annalisa Saracino; Laura Monno
Journal:  J Med Virol       Date:  2021-02-23       Impact factor: 20.693

6.  Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).

Authors:  Natalia Ruetalo; Bertram Flehmig; Michael Schindler; Lutz Pridzun; Angelika Haage; Marija Reichenbächer; Thomas Kirchner; Teresa Kirchner; Karin Klingel; Michael B Ranke; Andrea Normann
Journal:  Viruses       Date:  2021-11-23       Impact factor: 5.048

7.  Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects' eligibility?

Authors:  Tiago Paiva Prudente; Renato Gomes Castro; Marcos Antonio Candido; Roberta Luiza Rodrigues; Layane Marques de Souza; Maria do Rosario Ferraz Roberti
Journal:  Hematol Transfus Cell Ther       Date:  2021-11-04

8.  Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.

Authors:  Anne Gégout Petit; Hélène Jeulin; Karine Legrand; Nicolas Jay; Agathe Bochnakian; Pierre Vallois; Evelyne Schvoerer; Francis Guillemin
Journal:  Viruses       Date:  2021-06-04       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.